Dow approaches 30,000 after Moderna news
Neil Shearing, group chief economist at Capital Economics, wrote in a research note on Monday before the Moderna results were announced that vaccine breakthroughs show “there is finally light at the end of the tunnel.”
“Forget the fact President Trump has refused to concede defeat in the US election, or that Europe and the US remain gripped by new waves of the virus, or that another key Brexit deadline has passed and a ‘no deal’ exit is edging closer. Markets are focused on the increasing likelihood of a vaccine breakthrough,” he wrote.
Yet there are reasons for investors to temper their enthusiasm. It will take months for the vaccines to be distributed, and the number of coronavirus cases in the United States is surging. Big economies in Europe such as France, Germany, and the United Kingdom have been locked down for a second time.
Moderna said Monday that it expects to have roughly 20 million doses of its vaccine ready to ship in the United States by the end of this year. The company is on track to manufacture 500 million to 1 billion doses globally in 2021, it added.
Pfizer told CNN last week that it expects to have 50 million vaccine doses globally this year, and 1.3 billion in 2021.